Aytu BioPharma, Inc. reported a net loss of $13.6 million for the fiscal year ending June 30, 2025, a decrease from the $15.8 million loss recorded in the previous year. The company generated net revenue of $66.4 million, reflecting a modest increase of $1.2 million, or 2%, compared to $65.2 million in fiscal 2024. This growth was primarily driven by a 20% increase in revenue from the Pediatric Portfolio, which reached $8.8 million, while the ADHD Portfolio saw a slight decline to $57.6 million. The gross profit margin decreased to 69% from 75% due to rising costs associated with the ADHD Portfolio.
In a strategic shift, Aytu has focused on its core prescription business, leading to the suspension of its clinical development programs and the divestiture of its Consumer Health business, which was completed in July 2024. The company entered into a significant Exclusive Commercialization Agreement with Fabre-Kramer Holdings, Inc. in June 2025 to commercialize EXXUA, a new treatment for major depressive disorder (MDD) expected to launch in the fourth quarter of 2025. This product is anticipated to be a key growth driver, targeting a market with significant unmet needs.
Operationally, Aytu has streamlined its manufacturing processes by transferring production of its ADHD medications to a U.S.-based third-party manufacturer, which is expected to enhance profitability. The company reported no supply chain interruptions for its ADHD products during the fiscal year, allowing it to maintain high prescription levels. As of June 30, 2025, Aytu employed 83 individuals, with a focus on enhancing its commercial capabilities.
Looking ahead, Aytu's management remains cautious about external economic factors, including inflation and geopolitical tensions, which could impact supply chain stability and operational costs. The company is also facing potential competition from generic versions of its products, particularly Adzenys, with a trial related to patent infringement scheduled for December 2026. Aytu plans to continue evaluating strategic partnerships and opportunities to bolster its market position while aiming for profitability through its focused product portfolio.
About AYTU BIOPHARMA, INC
Aytu BioPharma, Inc. is a pharmaceutical company specializing in innovative treatments for central nervous system disorders, primarily major depressive disorder (MDD) and attention deficit hyperactivity disorder (ADHD). Its core products include EXXUA, a novel selective serotonin 5HT1a receptor agonist for MDD, and extended-release orally disintegrating tablets Adzenys and Cotempla for ADHD. The company also offers pediatric allergy and fluoride supplement products, marketing primarily in the U.S. through third-party wholesalers and an internal sales force.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.